J9065 Injection cladribine per 1 milligrams
Also known as: cladribine, Leustatin
Intravenous injection of cladribine, a purine nucleoside analog and adenosine deaminase-resistant nucleotide, dosed per 1 milligram.
In Plain Language
DNA-inhibiting cancer drug; leukemia treatment
Clinical Context
Used to treat hairy cell leukemia, chronic lymphocytic leukemia, and other lymphoproliferative disorders by inhibiting DNA synthesis.
RVU Information
CPT J9065 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9065?
CPT J9065 (Injection cladribine per 1 milligrams) is a J Codes (Drugs) code. Intravenous injection of cladribine, a purine nucleoside analog and adenosine deaminase-resistant nucleotide, dosed per 1 milligram.
How is J9065 administered?
CPT J9065 is administered by a healthcare provider, typically via injection or infusion. Used to treat hairy cell leukemia, chronic lymphocytic leukemia, and other lymphoproliferative disorders by inhibiting DNA synthesis. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9065 used?
Used to treat hairy cell leukemia, chronic lymphocytic leukemia, and other lymphoproliferative disorders by inhibiting DNA synthesis.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.